Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: Men Quad TT; MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; TetraMen-T

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Conjugate-vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Meningococcal A infections (In children) in USA and EU in 2019
  • 19 Jul 2018 Sanofi completes a phase III trial in Meningococcal group W-135 infections, Meningococcal group C infections and Meningococcal group A infections and Meningococcal group Y infections (In children, Prevention) in Russia, Mexico and South Korea (IM) (NCT03205371)
  • 12 Jun 2018 Sanofi plans a phase III trial for Meningococcal infections (Prevention, In infants) in Czech Republic, Finland, Italy, Romania, Spain and Sweden in November 2018 (NCT03547271)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top